Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial.AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19. The approval by the European Commission was based on results from the TACKLE Phase III COVID-19 treatment trial which showed one